Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M ReniA J Ferreri

Abstract

Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT). A phase II trial assessing temozolomide 150 mg/m(2)/day, for 5 days every 28 days in primary central nervous system (CNS) lymphoma (PCNSL) patients with negative human immunodeficiency virus (HIV) serology, Eastern Cooperative Oncology Group (ECOG) performance status (PS)<4, previously treated with high-dose methotrexate-containing (HD-MTX) chemotherapy and/or RT was started. Twenty-three patients were enrolled. Median age was 60 years. Five complete remissions (median duration 6+ months; range 2-36 months), one partial response, four stable disease (median duration 7.2 months, range 2-16.5 months), and 13 progressions were observed. No major toxicities were observed, apart grade 3 vomiting in a single cycle. Main grade 1-2 toxicities were: 15% nausea, 6% vomiting, 9% fatigue and 9% neurological symptoms. This is the first prospective trial assessing single-agent activity in PCNSL at failure. Although some patients had a poor PS and had been heavily pre-treated, temozolomide yielded 26% objective responses and was well tolerated without any major toxicity.

Citations

Sep 27, 2007·Journal of Neuro-oncology·Alfredo D VoloschinTracy Batchelor
Feb 9, 2012·Current Treatment Options in Oncology·Tara BloomSteven T Rosen
May 10, 2007·Current Neurology and Neuroscience Reports·Meltem Ekenel, Lisa M DeAngelis
Dec 22, 2004·Current Oncology Reports·Igor T Gavrilovic, Lauren E Abrey
Sep 1, 2006·Current Treatment Options in Neurology·Hendrik Pels, Uwe Schlegel
Jun 21, 2007·Current Treatment Options in Neurology·Meltem Ekenel, Lisa M Deangelis
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Alain P AlgaziJames L Rubenstein
Apr 6, 2000·Journal of the National Cancer Institute·M ReniE Villa
Jan 1, 2005·Current Opinion in Oncology·Khê Hoang-XuanCarole Soussain
Oct 12, 2005·Journal of Pediatric Hematology/oncology·Amanda M Termuhlen, Thomas G Gross
Jul 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christiane QuerfeldTimothy M Kuzel
Feb 5, 2005·Onkologie·Ulrich HerrlingerUNKNOWN Centers for Neuro-Oncology and Lymphoma, University of Tubingen, Germany
Dec 1, 2006·Neurosurgical Focus·Antonio M P Omuro, Lauren E Abrey
Dec 18, 2013·Current Treatment Options in Neurology·Patrick RothMichael Weller
Jul 27, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M SantistebanO Fernández Hidalgo
Nov 9, 2005·Expert Review of Neurotherapeutics·Jennifer I Stern, Jeffrey J Raizer
Sep 22, 2012·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·S F WongL Cher
Sep 13, 2011·Revue neurologique·A Gonzalez-AguilarK Hoang-Xuan
Oct 30, 2007·Neurologic Clinics·Nimish A Mohile, Lauren E Abrey
Jun 26, 2007·Critical Reviews in Oncology/hematology·Andrés J M Ferreri, Michele Reni
Apr 17, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Eric M BessellMichele Reni
Nov 23, 2006·Hematology/oncology Clinics of North America·Fabio M Iwamoto, Lisa M DeAngelis
Mar 22, 2005·European Journal of Haematology·Markus DietleinRoland Schnell
Jul 22, 2006·International Journal of Cancer. Journal International Du Cancer·Linda C ChuJames G Herman
Jun 27, 2007·Seminars in Radiation Oncology·Nimish A Mohile, Lauren E Abrey
Aug 9, 2005·Hematology/oncology Clinics of North America·Andrés J M Ferreri, Michele Reni
Aug 9, 2005·Hematology/oncology Clinics of North America·Carole SoussainNancy D Doolittle
May 19, 2009·Lancet Neurology·Patrick G Morris, Lauren E Abrey
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy Batchelor, Jay S Loeffler
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carole SoussainUNKNOWN Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Feb 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James L RubensteinLawrence D Kaplan
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T Batchelor
Mar 1, 2009·Therapeutic Advances in Neurological Disorders·Uwe Schlegel
Sep 11, 2009·Current Opinion in Neurology·Lauren E Abrey
Nov 11, 2005·Current Opinion in Neurology·Scott R Plotkin
Feb 28, 2007·British Journal of Cancer·M ReniA J M Ferreri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.